Evidence map›Paper›PMID 38957315›Full record

ArticleFrontiers in oncology2024

Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model.

Sadna Budhu, Kwanghee Kim, Wesley Yip, Stephen La Rosa, Sylvia Jebiwott, Liqun Cai, Aliya Holland, Jasmine Thomas, Dina Preise, Alex Somma and 6 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sadna BudhuSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medical Center, New York, NY, United States.
Kwanghee KimDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Wesley YipUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Stephen La RosaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Sylvia JebiwottDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Liqun CaiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Aliya HollandSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medical Center, New York, NY, United States.
Jasmine ThomasDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Dina PreiseDepartment of Plants and Environmental Sciences, The Weizmann Institute of Science, Rehovot, Israel.
Alex SommaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Benjamin GordonDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Avigdor ScherzDepartment of Plants and Environmental Sciences, The Weizmann Institute of Science, Rehovot, Israel.
Jedd D WolchokSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medical Center, New York, NY, United States.
Joseph ErinjeriDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Taha MerghoubSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medical Center, New York, NY, United States.
Jonathan A ColemanDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Introduction: Immunotherapy is revolutionizing the management of multiple cancer types. However, only a subset of patients responds to immunotherapy. One mechanism of resistance is the absence of immune infiltrates within the tumor. Methods: Here, we compare three different forms of localize tumor destruction therapies: radiation therapy (RT), vascular targeted photodynamic therapy (VTP) and cryoablation (Cryo), which are known to induce immunogenic cell death, with their ability to induce local and systemic immune responses in a mouse 4T1 breast cancer model. The effects of combining RT, VTP, Cryo with anti-PD1 was also assessed. Results: We observed that RT, VTP and Cryo significantly delayed tumor growth and extended overall survival. In addition, they also induced regression of non-treated distant tumors in a bilateral model suggesting a systemic immune response. Flow cytometry showed that VTP and Cryo are associated with a reduction in CD11b+ myeloid cells (granulocytes, monocytes, and macrophages) in tumor and periphery. An increase in CD8+ T cell infiltration into tumors was observed only in the RT group. VTP and Cryo were associated with an increase in CD4+ and CD8+ cells in the periphery. Conclusion: These data suggest that cell death induced by VTP and Cryo elicit similar immune responses that differ from local RT.

Indexed as

breast cancercryoablationimmune checkpoint blockaderadiation therapyvascular photodynamic therapy

Identifiers

PMID38957315
PMCPMC11217310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.